164 related articles for article (PubMed ID: 1619610)
1. Value of subcutaneous and intravenous pulsatile gonadotropin releasing hormone in polycystic ovary disease.
Saffan DS; Seibel MM
J Reprod Med; 1992 Jun; 37(6):545-51. PubMed ID: 1619610
[TBL] [Abstract][Full Text] [Related]
2. Induction of ovulation in clomiphene-resistant polycystic ovary syndrome with pulsatile GnRH.
Tan SL; Farhi J; Homburg R; Jacobs HS
Obstet Gynecol; 1996 Aug; 88(2):221-6. PubMed ID: 8692506
[TBL] [Abstract][Full Text] [Related]
3. Pulsatile GnRH therapy for the induction of ovulation in hypogonadotropic hypogonadism.
Blunt SM; Butt WR
Acta Endocrinol Suppl (Copenh); 1988; 288():58-65. PubMed ID: 3138867
[TBL] [Abstract][Full Text] [Related]
4. Ovulation induction with subcutaneous pulsatile gonadotropin-releasing hormone in various ovulatory disorders.
Saffan D; Seibel MM
Fertil Steril; 1986 Apr; 45(4):475-82. PubMed ID: 3082681
[TBL] [Abstract][Full Text] [Related]
5. Initial experiences with subcutaneous pulsatile human menopausal gonadotropin administration: successful induction of ovulation in patients with polycystic ovarian disease.
Rossmanith WG; Sterzik K; Wolf AS
Int J Fertil; 1987; 32(6):460-6. PubMed ID: 2891635
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
[TBL] [Abstract][Full Text] [Related]
8. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management.
Filicori M; Flamigni C; Campaniello E; Valdiserri A; Ferrari P; Meriggiola MC; Michelacci L; Pareschi A
J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216
[TBL] [Abstract][Full Text] [Related]
9. Induction of ovulation with pulsatile GnRH: comparison between subcutaneous and intravenous administration in the same patients.
Riolo A; Carioni E; Lerro S; Albano M; Crippa A; Gelli D; Bini M; Pisoni P
Acta Eur Fertil; 1987; 18(4):271-5. PubMed ID: 3134780
[TBL] [Abstract][Full Text] [Related]
10. [Induction of ovulation with pulsatile LHRH in anovulatory women].
Masaoka K; Kumasaka T
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jun; 36(6):937-46. PubMed ID: 6431037
[TBL] [Abstract][Full Text] [Related]
11. Benefits of continuous physiological pulsatile gonadotropin-releasing hormone therapy in women with polycystic ovarian syndrome.
Corenthal L; Von Hagen S; Larkins D; Ibrahim J; Santoro N
Fertil Steril; 1994 Jun; 61(6):1027-33. PubMed ID: 8194612
[TBL] [Abstract][Full Text] [Related]
12. Clomiphene citrate-resistant polycystic ovary syndrome. Preventing multifollicular development.
Ergür AR; Yergök YZ; Ertekin A; Küçük T; Müngen E; Tütüncü L
J Reprod Med; 1998 Mar; 43(3):185-90. PubMed ID: 9564642
[TBL] [Abstract][Full Text] [Related]
13. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
[TBL] [Abstract][Full Text] [Related]
14. [Treatment options of clomiphene-resistant polycystic ovary syndrome related infertility].
Liang X; Zhuang G; Zhou C
Zhonghua Fu Chan Ke Za Zhi; 2000 Oct; 35(10):591-3. PubMed ID: 11372407
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome.
Timmerman-van Kessel EC; Cikot RJ; Dargel-Donkers EJ; Zwertbroek W; van Dop PA; Schoot DC
Fertil Steril; 2000 Jun; 73(6):1145-8. PubMed ID: 10856472
[TBL] [Abstract][Full Text] [Related]
16. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
Filicori M; Flamigni C; Meriggiola MC; Ferrari P; Michelacci L; Campaniello E; Valdiserri A; Cognigni G
J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
[TBL] [Abstract][Full Text] [Related]
17. A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level.
Parsanezhad ME; Alborzi S; Namavar Jahromi B
Arch Gynecol Obstet; 2004 Jan; 269(2):125-9. PubMed ID: 14648180
[TBL] [Abstract][Full Text] [Related]
18. Induction of ovulation with pulsatile gonadotropin releasing hormone (GnRH) in anovulatory women.
Cignitti M; Mazzarini A; Pini A; Garzetti GG; Romanini C
Acta Eur Fertil; 1990; 21(5):235-8. PubMed ID: 2132474
[TBL] [Abstract][Full Text] [Related]
19. Ovulation induction with pulsatile luteinizing releasing hormone in women with clomiphene citrate-resistant polycystic ovary-like disease: clinical results.
Burger CW; Korsen TJ; Hompes PG; van Kessel H; Schoemaker J
Fertil Steril; 1986 Dec; 46(6):1045-54. PubMed ID: 3096792
[TBL] [Abstract][Full Text] [Related]
20. Ovulation induction and pregnancy in women with hypothalamic amenorrhea treated with intermittent gonadotropin-releasing hormone.
Corenblum B; Mackin J; Taylor PJ
J Reprod Med; 1985 Oct; 30(10):736-40. PubMed ID: 3934370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
